{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:41Z","timestamp":1791105701206,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1124\/jpet.110.169532","type":"journal-article","created":{"date-parts":[[2010,10,22]],"date-time":"2010-10-22T04:29:05Z","timestamp":1287721745000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"336","author":[{"given":"Tom H.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine A.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilmin P.","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Todd","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.169532_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem Biol"},{"key":"10.1124\/jpet.110.169532_bib2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.expneurol.2009.07.019","article-title":"Sleep disorders in Parkinson\u2019s disease: the contribution of the MPTP non-human primate model","volume":"219","author":"Barraud","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.110.169532_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/bbrc.1999.0254","article-title":"Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function","volume":"256","author":"Bisogno","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.110.169532_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00002826-199010000-00006","article-title":"Nigrostriatal damage is required for induction of dyskinesias by l-DOPA in squirrel monkeys","volume":"13","author":"Boyce","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.110.169532_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.110.169532_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/me.2009-0239","article-title":"N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119","volume":"24","author":"Chu","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1124\/jpet.110.169532_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"key":"10.1124\/jpet.110.169532_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","article-title":"The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation","volume":"60","author":"Di Marzo","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.110.169532_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fasebj.14.10.1432","article-title":"Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson\u2019s disease","volume":"14","author":"Di Marzo","year":"2000","journal-title":"FASEB J"},{"key":"10.1124\/jpet.110.169532_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.wco.0000137528.23126.41","article-title":"Dopamine dysregulation syndrome in Parkinson\u2019s disease","volume":"17","author":"Evans","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/jpet.110.169532_bib11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.110.169532_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.104.078980","article-title":"Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3\u2032-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation","volume":"313","author":"Fegley","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.169532_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson\u2019s disease","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurol"},{"issue":"Suppl 3","key":"10.1124\/jpet.110.169532_bib14","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1002\/mds.22021","article-title":"Levodopa-related motor complications\u2013phenomenology","volume":"23","author":"Fox","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.169532_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.110.169532_bib16","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.110.169532_bib17","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.169532_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.169532_bib19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.biopsych.2008.08.008","article-title":"Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates","volume":"64","author":"Justinova","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.110.169532_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat Med"},{"key":"10.1124\/jpet.110.169532_bib21","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.169532_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","article-title":"Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson\u2019s disease models","volume":"445","author":"Kreitzer","year":"2007","journal-title":"Nature"},{"key":"10.1124\/jpet.110.169532_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuropharm.2006.04.016","article-title":"A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and l-DOPA induced locomotion in normal and reserpine-treated rats","volume":"51","author":"Lee","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.169532_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.104.069401","article-title":"Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity","volume":"311","author":"Lichtman","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.169532_bib25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1046\/j.1471-4159.2003.01759.x","article-title":"Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism","volume":"85","author":"Maccarrone","year":"2003","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.110.169532_bib26","article-title":"Blockade of nicotine reward and reinstatement by activation of \u03b1-type peroxisome proliferator-activated receptors","author":"Mascia","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.110.169532_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev.biochem.74.082803.133450","article-title":"Structure and function of fatty acid amide hydrolase","volume":"74","author":"McKinney","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"10.1124\/jpet.110.169532_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.110.169532_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-006-0689-4","article-title":"Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality","volume":"192","author":"Naidu","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.110.169532_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O\u2019Sullivan","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1124\/jpet.110.169532_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2006.00021.x","article-title":"Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597)","volume":"12","author":"Piomelli","year":"2006","journal-title":"CNS Drug Rev"},{"key":"10.1124\/jpet.110.169532_bib32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/jnp.14.4.438","article-title":"Clinical features and comorbidity of mood fluctuations in Parkinson\u2019s disease","volume":"14","author":"Racette","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1124\/jpet.110.169532_bib33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1111\/j.1460-9568.2007.05521.x","article-title":"Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret","volume":"25","author":"Sharkey","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.110.169532_bib34","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"10.1124\/jpet.110.169532_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ijo.2009.262","article-title":"FAAH deficiency promotes energy storage and enhances the motivation for food","volume":"34","author":"Tourino","year":"2010","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/jpet.110.169532_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.biopsych.2005.08.019","article-title":"Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications","volume":"59","author":"Tzavara","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.110.169532_bib37","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1432-1033.2004.04081.x","article-title":"Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels","volume":"271","author":"van der Stelt","year":"2004","journal-title":"Eur J Biochem"},{"key":"10.1124\/jpet.110.169532_bib38","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J"},{"key":"10.1124\/jpet.110.169532_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"\u03b11-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.169532_bib40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.110.169532_bib41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.110.169532_bib42","doi-asserted-by":"crossref","first-page":"16511","DOI":"10.1073\/pnas.0902743106","article-title":"The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo","volume":"106","author":"Whyte","year":"2009","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524462198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524462198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.169532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:24:48Z","timestamp":1740018288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524462198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0022356524462198"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.169532","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.169532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}